Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.

Dana Horakova,Aaron Boster,Antonio Bertolotto,Mark S. Freedman,Isabel Firmino,Steven Cavalier,Alan Jacobs,Karthinathan Thangavelu,Nadia Daizadeh,Elizabeth Poole,Darren P. Baker,David Margolin,Tjalf Ziemssen,Camms Investigators

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.

2020

Dana Horakova
Aaron Boster
Antonio Bertolotto
Mark S. Freedman
Isabel Firmino
Steven Cavalier
Alan Jacobs
Karthinathan Thangavelu
Nadia Daizadeh
Elizabeth Poole
Darren P. Baker
David Margolin
Tjalf Ziemssen
Camms Investigators

BackgroundFew data exist concerning conversion to secondary progressive MS in patients treated with disease-modifying therapies.ObjectiveDetermine the proportion of alemtuzumab-treated patients con...

Keywords:

in patient
Secondary progressive multiple sclerosis
Multiple sclerosis
Internal medicine
relapsing remitting
Alemtuzumab
Medicine
disease progression
secondary progressive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations